You walk down the streets of Manhattan. You smelt cannabis on every corner there. So with that, absolutely, we’re going to look to grow. And I’m very clear in our headlines of our press release today. We’re going to diversify this company into multiple categories that have adjacency to the cannabis business. And no, we’re not out there buying Molson Coors, but we want to be that large craft brewer out there that owns multiple brands like we did with SweetWater Lake. We did with Green Flash like we have with Montauk like we have with Breckenridge and looking at other spirits businesses and like we have with Manitoba Harvest. So, you’re absolutely correct on that. Your second question. Your second.
Pablo Zuanic: Do you want to repeat the second question?
Irwin Simon: No, no, no. I got — no, I just. No, I was going to answer your second question. Listen, right now, being on the NASDAQ is important for us, having the trading volume, having the shareholders that we have — right now, it would not be of interest to us to be exiting the NASDAQ and moving to the TSX or an exchange that allows us to own U.S. assets. And if Canopy does it, good luck to them. But right now, our focus is to diversify our business grow where we have strong, strong cannabis opportunities in Canada where we have strong opportunities in Europe and grow our consumer packaged goods business because one day, you will see beer with THC and in the U.S., one day, you’ll see spirits with THC in the U.S. And if anything, where is the cannibalization going to come from, it will come from the spirits businesses. So our focus is not to move away from the NASDAQ now.
Operator: Next question is from the line of Matt Bottomley with Canaccord. Please proceed with your question.
Matt Bottomley: Just wanted to pivot back to the M&A side of things, particularly in the U.S. So clearly, you guys have had a very specific strategy of acquiring adjacent businesses to THC that are self-sustaining, but when you look at some of the other deals that have been done in this space for sort of optionality. I know that the deal you guys had done with MedMen, there were some financial cash flow considerations to that that may make sense. But do you think just given the frustration of nothing happening at the federal level, changes your view on how to allocate capital or how to position yourself given some of the headlines or lack thereof in December? And then also just Irwin on your comment of anticipating a legalization event in 2024, do you think that’s more likely from what Joe Biden had said with respect to some of his initiatives? Or do you think something could actually happen in this new Congress, which is now split?
Irwin Simon: So, I wish the speaker of the house cannabis was one of his focuses, but it’s absolutely not. Listen, I come back, and I’ve said this before, we are not going to buy options and by pieces of U.S. companies. There’s a lot of good things happening with MedMen and we’re excited about how the cleanup has been going there and what is ultimately happening. And upon legalization, we’d be very interested in having that asset as part of Tilray upon legalization. In regards to legalization, listen, I’m frustrated that legalization or nothing, whether it’s safe bank, whether it’s Mor-Act whether it’s de-scheduling, whatever, nothing has happened within cannabis and almost all the different faces out there. So with that for our business, we got to focus on Canada, where it’s legal.
